Futibatinib
|
|
|
- CAS-Nr.
- 1448169-71-8
- Englisch Name:
- Futibatinib
- Synonyma:
- Futibatinib;1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one;CS-2344;CS-2681;FGFR-IN-1;2H6]-Futibatinib;Futibatinib Crude;FUTIBATINIB;TAS120;TAS-120 (Futibatinib);Bexagliflozin Impurity 14
- CBNumber:
- CB03155059
- Summenformel:
- C22H22N6O3
- Molgewicht:
- 418.45
- MOL-Datei:
- 1448169-71-8.mol
|
Futibatinib Eigenschaften
- Siedepunkt:
- 733.8±60.0 °C(Predicted)
- Dichte
- 1.33±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- L?slichkeit
- DMSO:38.0(Max Conc. mg/mL);90.81(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);71.69(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.38(Max Conc. mM)
Ethanol:0.5(Max Conc. mg/mL);1.19(Max Conc. mM)
- Aggregatzustand
- A crystalline solid
- pka
- 3.60±0.30(Predicted)
- Farbe
- White to yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Futibatinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Futibatinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.
Application
Futibatinib has received accelerated approval in the U.S. for the treatment of patients with advanced solid tumors that carry FGFR gene mutations. In addition, it is approved in the U.S. for the treatment of patients with cholangiocarcinoma whose disease has progressed after prior chemotherapy. The development and approval of Futibatinib provides a new targeted treatment option for cancer patients that carry FGFR mutations, especially for those who are resistant or intolerant to existing treatment options.
Trademarks
Lytgobi
in vitro
Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR.
in vivo
Futibatinib (TAS-120) (3, 30, 100 mg/kg/day, p.o.) exerts an anti-tumor
effect in mice. Futibatinib (TAS-120) shows anti-tumor effect by
administering at moderate intervals, such as intermittent administration
of every other day dosing and 2 times/week, and reducing the sustained
elevation and weight suppression blood phosphorus level, and take a
antitumor effective as daily administration.
Futibatinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Futibatinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 98)Lieferanten
- FGFR-IN-1
- FGFR-IN-1;FUTIBATINIB;TAS-120
- FUTIBATINIB;TAS120
- TAS-120 (Futibatinib)
- CS-2681
- CS-2344
- 2-Propen-1-one, 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-
- 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one
- Futibatinib
- (S)-1-(3-(4-Amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one
- 2H6]-Futibatinib
- FGFR,Inhibitor,TAS-120,Futibatinib,Fibroblast growth factor receptor,inhibit,TAS 120
- 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
- Futibatinib Crude
- Bexagliflozin Impurity 14
- Futibatinib, 10 mM in DMSO
- 1448169-71-8
